South Africa has pivoted to Johnson & Johnson COVID-19 vaccines after suspending its AstraZeneca rollout, citing concerns over efficacy against the locally dominant variant. Preliminary trial data revealed the AstraZeneca vaccine offered minimal protection against the South African strain, prompting a swift strategy shift.
Health officials emphasized the move prioritizes public safety, with J&J doses now being administered nationwide. The transition highlights global challenges in balancing vaccine access with evolving scientific insights, as countries adapt to emerging variants.
Reference(s):
cgtn.com
